Lv11
30 积分 2026-01-24 加入
Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study
16小时前
已完结
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
16小时前
已完结
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study
16小时前
已完结
Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults
7天前
已完结
Association of age at cardiometabolic disease diagnosis with mortality and life expectancy: 8.4 million person-years of observation
21天前
已完结
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide
1个月前
已完结
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide
1个月前
已关闭
Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome
1个月前
已关闭
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
1个月前
已完结
Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2个月前
已完结
419-P: Association of Remnant Cholesterol (rem-C) with Kidney Disease Progression in People with Type 2 Diabetes (T2D)
皖公网安备34019202002308
